

# Seed Grants to Promote Translational Research

### History



#### Arizona's Bioscience Roadmap

Goal #2:

Increase the ability of research-performing institutions to turn bench research results into improved disease/illness prevention, detection, and treatment.

• Since 2013: 65 grants, over \$7.2 million





## Eligibility



- Scientists/clinicians/others affiliated with **Arizona-based** research institutions and health-care systems.
- Project addresses a clearly defined, compelling clinical need—bringing new products/services to benefit patients.
- Precision medicine, diagnostics, devices, therapeutics, and health-care delivery processes.
- Clear path to pre-commercialization phase (can also be open-source).
- Letter of support from institution's vice president of research or equivalent.



#### Benefits



- 10 projects funded: \$100K each for 18 months
- Follow-on funding: \$100K for up to two projects for 12 months
- Research/industry advisors
- Workshops and learning opportunities
- Referrals to programs, resources, and experts
- Arizona's Bioscience Roadmap Steering Committee



### Use of funds



- Program-related lab expenses (materials, support staff, analysis)
- Prototype development, testing, and validation
- Animal-model tests
- Publication of data
- Development/refinement of business plan and customer exploration
- Development of proposals for follow-on funding from SBIR, NIH grants, angel investments, philanthropic funds, etc.
- Up to 10% Indirect Costs
- > May not be used for compensation of principal investigator(s) or prior debt.



### Expectations



- Quarterly reports and presentations
- Secure or plans to secure new funding
- Final report/presentation
- Institutional Review Board approval in place prior to start of grant
- Plan for intellectual property—including ownership/licensing of technology



# Recently Funded Projects



HistaHeal – Bioactive Dressing for Diabetic Wounds – Jordan Yaron Ph.D., Arizona State University


**Novel Approach to Eliminate Opioid Addiction in Pain Management** – John Streicher Ph.D., University of Arizona College of Medicine – Tucson

**Targeting TDP-43 for Neurodegenerative Diseases** – Xinglong Wang Ph.D., University of Arizona College of Pharmacy

**Neurostimulator Device for the Assessment of Consciousness** – Brandon Fox M.D., Barrow Neurological Institute

Sepsis Dx - Septic Shock Screening Device – Jeff La Belle Ph.D., Grand Canyon University

**High Throughput Biomanufacturing of Encapsulated Cell Products** – Jessica Weaver Ph.D., Arizona State University



**Gynecological Cancer and Disease Diagnostic with At-Home Test Collection** – Melissa Herbst-Kralovetz, Ph.D., University of Arizona College of Medicine - Phoenix

# **Application Portal**



	Don't have a SurveyMonkey Apply account?
<b>♣</b> Apply	
Log in with	G
OR Email	
Password	◆
Forgo	t your password?
LOG IN	



# **Application Portal**



	tasks complete	
Last e	dited: Oct 13 2020	01:13 PM (MST)
F	REVIEW	SUBMIT
Deadli	ine: Nov 2 2020 05:	00 PM (MST)
JG	Juliet Gomez (O julietkf@gmail.c	
Ad	id collaborator	
1		



## **Application Content**



- Basic contact info
- Project lay summary
  - 300 words
- Application presentation deck
- Letter of support
  - Signed by institution's president, CEO, senior VP of research or designee



#### Presentation Deck



Link to slide deck template

- 1. Title Slide
- 2. Clinical need and scale of the problem
- 3. Current solutions / limitations
- 4. Proposed new solution and expected benefits
- 5. Development work done to-date
- 6. Development work done to-date (ctd.)
- 7. Validation (include mention of publications, customer feedback, etc.)



### Presentation Deck, ctd.




- 8. Plan for commercialization/licensing
- 9. Regulatory requirements and plan to address
- 10. Project plan for grant period, including goals and key milestones
- 11. Current intellectual property (IP) and IP strategy
- 12. Funding received to date and future funding plans
- 13. Project team/resources and environment
- 14. Detailed breakout of proposed use of Flinn grant funds
- 15. What else reviewers should know about your project



# Saving and Editing the Application







### Deadline



5:00 p.m.

September 26, 2024



#### Review Process



- Review-panel composition
- Scoring criteria:
  - Clearly defined clinical need
  - Technical overview and market opportunity
  - Project plan, including goals and milestones
  - Project team
  - Planned use of grant funds

(Rubric available on website)

Notification: mid-December 2024



#### Seed Grants to Promote Translational Research Scoring Rubric - 2024



l.	Clinical Need/Problem & Solution  ☐ Solves compelling clinical need ☐ Clear understanding of current standard of care ☐ Proposed solution provides significant benefits	<ul> <li>V. Proposed used of funds</li> <li>□ Detailed use of funds for the \$100,000</li> <li>□ Will the proposed use of funds help achieve the goals/milestones of the grant period?</li> </ul>
II.	<ul> <li>Development of Research/Validation</li> <li>☐ Significant research/work already accomplished</li> <li>☐ Validation performed (publications, customer feedback, etc.)</li> </ul>	VI. Project team, resources, and environment  ☐ Good project team with leadership and/or technical/scientific experience and knowledge ☐ Will utilize institution resources to eventually
III.	Commercialization/Licensing Strategy  ☐ Understanding of path to commercialization ☐ Clinical partners/relationships established ☐ Milestones/traction ☐ Plan for addressing regulatory path and IP strategy	translate project Realizes personnel needs for the future  VII. Executive summary and overall proposal Information supported by data Effectively written summary Well-structured proposal with detailed outcomes identified
IV.	Project plan for grant period – Goals and key milestones  Realistic plan, goals, and milestones detailed Has project received significant funding to date?  Plans for future funding discussed	Questions? Feel free to reach out to Mary O'Reilly, Ph.D. at moreilly@flinn.org  Visit flinn.org/seedgrants for more information and to apply.



#### Lessons Learned

- Early research without a clearly identified, compelling clinical need.
- Poorly discussed path toward market.
- Poorly discussed IP strategy.
- Too much text and technical information.
- Team composition that doesn't represent breadth of experience needed complete next phase of work.
- Executive summary not provided in layperson terms.





Mary O'Reilly, Ph.D.

moreilly@flinn.org

flinn.org/seedgrants